FSSAI opens three adjudication proceedings against Nestlé India over infant-product claims

India’s food regulator has initiated three cases involving promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, plus an alleged biotin non-conformity in a follow-up formula. Nestlé India disputes FSSAI’s interpretation and says its products comply with applicable regulations.

— Source publishedFri, 18 Sept, 2026, 18:35 IST·First seen Fri, 18 Sept, 2026, 19:00 IST·Source Financial Express · BrandWagon

What happened

FSSAI initiated three adjudication cases against Nestle India over promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and biotin non-conformity

Key facts

  • Three separate adjudication proceedings
  • Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
  • Section 3 of the Infant Milk Substitutes Act, 1992
  • Nestle shares closed down 1.38% at Rs 1,353.10

What changed

FSSAI initiated three adjudication cases against Nestle India over promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and biotin non-conformity in a follow-up formula. Nestle disputes the regulator’s interpretation and says its products comply with regulations.

Why this matters

The FSSAI proceedings add near-term compliance, reputational, and possible sales-risk pressure to Nestlé India’s sensitive infant-nutrition portfolio, despite the company’s stated disagreement with the regulator.

What to watch

  • FSSAI adjudication notices, hearing dates, interim directions, final orders, penalties, or mandated corrective actions.
  • Whether the alleged biotin issue is confirmed by regulator testing and whether it results in batch withdrawal, recall, relabeling, or reformulation.
  • Any expansion from the named NAN Excella Pro Stage 1 and Lactogen Pro 1 products to additional Nestlé India infant-nutrition SKUs.
  • Evidence that FSSAI is applying the same interpretation to other formula manufacturers, indicating a sector-wide enforcement shift rather than an isolated dispute.
  • Retailer delistings, e-commerce content changes, distributor inventory actions, or unusual changes in promotional intensity for affected products.